Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Request metadata listed "Tenax Therapeutics," but the filing text identifies the registrant as Synthetic Blood International, Inc.)
Reporting Period: Quarterly period ended January 31, 2004 (Nine months ended January 31, 2004).
Status: Development stage company focused on perfluorocarbon-based medical products, including Oxycyte (blood substitute), Fluorovent (lung treatment), and a glucose biosensor implant.
Going Concern: The filing states substantial doubt exists regarding the company's ability to continue as a going concern due to an accumulated deficit of $20.4 million and reliance on future financing.
Key Financial Metrics
| Metric | Three Months Ended Jan 31, 2004 | Nine Months Ended Jan 31, 2004 | Balance Sheet (Jan 31, 2004) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(813,331) | $(1,725,667) | Accumulated Deficit: $(20,426,397) |
| Operating Expenses | $815,523 | $1,742,534 | N/A |
| Cash and Equivalents | N/A | N/A | $722,541 |
| Working Capital | N/A | N/A | $496,021 |
| Current Liabilities | N/A | N/A | $333,755 |
| Cash Flow (Operating) | N/A | $(1,259,005) | N/A |
| Cash Flow (Financing) | N/A | $1,902,225 | N/A |
Material Changes vs. Prior Period
- Net Loss: The net loss for the three months ended Jan 31, 2004, increased to $813,331 from $464,498 in the prior year period. For the nine months, the loss decreased slightly to $1,725,667 from $1,891,868.
- Expenses: Research and Development (R&D) expenses for the three months increased to $501,488 (from $243,214) due to Phase I clinical trial costs for Oxycyte. Conversely, nine-month R&D expenses decreased to $1,000,198 (from $1,256,761) due to reduced consulting and lab supply costs compared to the prior year's late-stage animal studies.
- Liquidity: Cash and cash equivalents increased significantly from $178,442 at April 30, 2003, to $722,541 at January 31, 2004, driven by financing activities.
- Liabilities: Accounts payable surged from $12,235 to $291,710, and accrued liabilities increased from $2,298 to $42,045.
Guidance, Outlook, and Risks
- Product Development: Phase I clinical studies for Oxycyte were completed in December 2003 with results meeting expectations. The company plans to begin Phase II studies in Q2 2004, estimating a cost of approximately $2 million and a one-year timeline.
- Financing Needs: Management believes current cash ($722,541) is sufficient only through April 2004. Continued operations depend on obtaining additional financing for Phase II/III trials and commercialization.
- Recent Capital Raise: The company completed a $2,000,000 private placement of common stock to foreign investors (Regulation S) during the period, with final shares issued in February 2004. This included issuing warrants for 4,000,000 shares and agreeing to issue approximately 12,000,000 shares as compensation to placement consultants.
- Risks: Substantial doubt exists regarding the company's ability to continue as a going concern. There is no assurance that necessary funding will be obtained. The company has no revenue and relies entirely on equity/debt financing.
Investor Verification Checklist
- Capital Runway: Verify if the company has secured funding beyond April 2004, as current cash reserves are insufficient for the estimated $2 million Phase II trial.
- Private Placement Completion: Confirm the final closing of the $2 million private placement and the issuance of the 12 million shares promised to consultants.
- Phase II Protocol: Review the FDA submission status for the Phase II clinical trial protocols mentioned as being in preparation.
- Related Party Transactions: Scrutinize the $126,000 paid to a contract manufacturer where an officer is a minority shareholder/director.
- Stock Dilution: Assess the impact of the 12 million shares to be issued to consultants and the 4 million warrants on existing shareholder equity.